JP Morgan Chase’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
Other funds holding LGND
VPM
VCM
NAMI
CC
JP Morgan Chase's LGND Position: Q1 2026 in Review
JP Morgan Chase increased its Ligand Pharmaceuticals (LGND) stake by 52% in Q1 2026, buying an estimated $5.87M and bringing the position to 86,274 shares worth $16.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2235.
JP Morgan Chase first reported a position in LGND in Q2 2013 and has held it in 45 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- JP Morgan Chase held 86,274 shares of Ligand Pharmaceuticals worth $16.6M as of Q1 2026.
- JP Morgan Chase bought 29,684 Ligand Pharmaceuticals shares in Q1 2026, an estimated $5.87M.
- Ligand Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2235 holding.
- JP Morgan Chase first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.